Van ECK Associates Corp Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)

Van ECK Associates Corp raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHRFree Report) by 4.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,539 shares of the biotechnology company’s stock after buying an additional 475 shares during the quarter. Van ECK Associates Corp’s holdings in United Therapeutics were worth $2,421,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the 1st quarter valued at about $32,000. GAMMA Investing LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $43,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares in the last quarter. Janiczek Wealth Management LLC raised its holdings in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 46 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on UTHR. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Oppenheimer lifted their price target on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. Wells Fargo & Company boosted their price target on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $312.22.

Get Our Latest Report on UTHR

Insider Activity

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $320.45, for a total value of $1,153,620.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $41,658.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Monday, July 1st. The stock was sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $41,658.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Nilda Mesa sold 266 shares of United Therapeutics stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total value of $84,742.28. Following the transaction, the director now owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Insiders sold a total of 112,544 shares of company stock worth $29,811,740 in the last quarter. 12.50% of the stock is owned by company insiders.

United Therapeutics Trading Up 1.1 %

UTHR opened at $314.56 on Friday. The stock has a market cap of $13.95 billion, a PE ratio of 14.87, a PEG ratio of 1.38 and a beta of 0.55. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The business has a 50 day moving average of $282.72 and a 200-day moving average of $246.34. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $325.00.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter last year, the business posted $4.86 EPS. Equities research analysts predict that United Therapeutics Co. will post 24.73 earnings per share for the current fiscal year.

About United Therapeutics

(Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRFree Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.